All In Biotech

NDA 208082 · Teva Branded Pharm

Austedo

Deutetrabenazine · Oral

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 3, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

18

11 Phase 3, 2 recruiting

FAERS reports

5,937

2,709 serious, 498 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON’S DISEASE AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of AUSTEDO XR or AUSTEDO must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. AUSTEDO XR and AUSTEDO are...

What it is approved for

From the label in effect Feb 28, 2025.

AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 )] AUSTEDO XR and AUSTEDO are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of: Chorea associated with Huntington’s disease ( 1 ) Tardive dyskinesia ( 1 )

Mechanism: The precise mechanism by which deutetrabenazine exerts its effects in the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (α-dihydrotetrabenazine [HTBZ] and β-HTBZ) of deutetrabenazine, are reversible inhibitors of VMAT2, resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 24, 2021 Supplement 9 · Efficacy · priority review LetterLabel
  • Apr 3, 2017 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
3 products under this application
  • AUSTEDO · DEUTETRABENAZINE 9MG · TABLET, ORAL · Prescription · TE AB
  • AUSTEDO · DEUTETRABENAZINE 12MG · TABLET, ORAL · Prescription · TE AB
  • AUSTEDO · DEUTETRABENAZINE 6MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Deutetrabenazine" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective778
  • death435
  • depression388
  • dyskinesia386
  • tremor294
  • product use issue280
  • somnolence271
  • suicidal ideation260
  • fall255
  • insomnia255
  • product use in unapproved indication255
  • fatigue248

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
201786
2018405
2019601
2020708
2021778
2022527
2023503
2024950
2025780
2026598

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Austedo (Deutetrabenazine)

2024 spending

$1.07B

Beneficiaries

18,418

162,212 claims

Per beneficiary

$57,927

$103.14 per unit

View as table
YearSpending
2020$530,460,830
2021$666,002,295
2022$890,369,750
2023$1,123,439,045
2024$1,066,901,471

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.